How Chinese drug makers are tackling Western dominance in US$16 billion Parkinson’s race

Chinese biomedical companies are increasingly challenging Western dominance in the development of Parkinson's disease treatments, targeting a market projected to reach $16 billion in the next decade. These companies are utilizing advanced technologies like cell therapies, gene therapies, and non-invasive ultrasounds to create novel treatments. While many candidates are in early-stage trials, this represents a significant effort to address the limitations of existing medications like levodopa, which only manage symptoms and lose effectiveness over time. The goal is to develop therapies that can halt or slow the progression of Parkinson's disease. This research and development is taking place in China, with the intention of competing in the global market.